PAVmed launches $9.4M at-the-market stock offering
What's the deal? PAVmedDealroom has a profile for this one. Try Dealroom → (Nasdaq: PAVM) has entered a sales agreement with A.G.P./Alliance Global PartnersDealroom has a profile for this one. Try Dealroom → to sell up to $9.4 million of common stock through an at-the-market offering. The medical device company disclosed the deal in a Form 8-K filed September 9, 2026.
How it works: Shares will be sold from time to time at prevailing market prices under PAVmed's existing shelf registration, which the SEC declared effective on April 15, 2025. A.G.P. serves as sales agent and earns a 3% commission on gross sales.
What's the endgame? PAVmed said proceeds will fund working capital and general corporate purposes. The structure lets it raise cash gradually rather than draw down existing reserves.
What could go wrong? The raise could meaningfully dilute existing shareholders. Because sales occur at the company's discretion and at market prices, dilution may build up over time, while net proceeds shrink after the 3% commission and added transaction fees.
The signal: For a company of PAVmed's size, $9.4 million is material — a sign it plans to bankroll operations through new share sales. Either party can end the arrangement with ten business days' written notice.
Read more: minichart.com.sg
Image credit: Generated with Gemini
